Fig. 3From: Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in FranceCost-effectiveness acceptability curves for the treatment of metastatic HER2-negative breast cancerBack to article page